The combination of MnO2@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer
It can be found from a large number of cancer treatments that use of anti-cancer drugs alone often presents low efficacy and high side effects. This study aims to develop a new drug carrier with tumor-specific response, controlled release in vivo and high tumor-suppressive property. Inorganic nano-m...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Taylor & Francis Group
2022-12-01
|
| Serie: | Drug Delivery |
| Soggetti: | |
| Accesso online: | http://dx.doi.org/10.1080/10717544.2022.2032872 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|